Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Ribupatide in obesity + PMOS (NCT06595797)

Ribupatide in obesity + PMOS (NCT06595797)

Ribupatide (HRS9531) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Ribupatide (HRS9531)
Population
obesity
Phase
2
Participants
158
Duration
32 weeks
Registry
NCT06595797

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
1 mgobesity china32158—−10.0 % vs −2.6 %
Δ −7.4 pp
—0.0 vs 0.0———0.0 vs 0.0—congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (3)
  • 1 mg · weight_tp · abstract
    mean percentage weight change was -10.0%, -15.1% and -20.2% for the ribupatide 1
  • 1 mg · ae_dc · abstract, Results (last sentences)
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.
  • 1 mg · sae · abstract, Results (last sentences)
    No serious AEs, adverse events of special interest (AESI) or AEs leading to treatment discontinuation occurred.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Ribupatide in obesity + PMOS (NCT06595797). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-in-obesity-pmos/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.